findmyKOL
Clinical trialNCT01650376UnknownPhase 1/PHASE2Interventional

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

SponsorSwedish Medical CenterEnrollment52Stage III Ovarian CancerStage IV Ovarian CancerUterine Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine the maximum tolerated dose (MTD) of the investigational agent, olaparib, to give in combination with carboplatin and paclitaxel in patients with relapsed ovarian cancer or uterine cancer. Furthermore, the investigators intend to study the safety and tolerability of the study treatment, response to treatment, time to disease progression, and overall survival.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Swedish Cancer Institute Edmonds Campus

    Edmonds, Washington, United States

  • Swedish Cancer Institute Issaquah Campus

    Issaquah, Washington, United States

  • Pacific Gynecology Specialists

    Seattle, Washington, United States

  • Swedish Cancer Institute Ballard Campus

    Seattle, Washington, United States

  • Swedish Medical Center Cancer Institute

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Carboplatin →Olaparib →Paclitaxel →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 2012
Primary completion
31 Dec 2018
Completion
31 Dec 2019
Last update posted
23 Mar 2018
Registered enrollment
52
Registry id
NCT01650376
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.